A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
机构：[1]Chinese Acad Med Sci, Canc Hosp, Hepatobiliary Surg, Beijing, Peoples R China[2]Harbin Med Univ, Affiliate Tumor Hosp, Harbin, Heilongjiang, Peoples R China[3]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Hepatobiliary Surg, Beijing, Peoples R China[4]Peking Union Med Coll Hosp, Hepatobiliary Surg, Beijing, Peoples R China[5]Capital Med Univ, Xuanwu Hosp, Hepatobiliary Surg, Beijing, Peoples R China首都医科大学宣武医院普通外科
第一作者机构：[1]Chinese Acad Med Sci, Canc Hosp, Hepatobiliary Surg, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Yan S.,Zhang Y.,Bi X.,et al.A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection[J].ANNALS OF ONCOLOGY.2019,30:-.
APA：
Yan, S.,Zhang, Y.,Bi, X.,Zhao, J.,Du, S....&Zhao, H..(2019).A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection.ANNALS OF ONCOLOGY,30,
MLA：
Yan, S.,et al."A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection".ANNALS OF ONCOLOGY 30.(2019):-
医学